- US-listed companies
- NEUROCRINE BIOSCIENCES INC
- Income statement
NEUROCRINE BIOSCIENCES INCNBIX
Market cap
$15.4B
P/E ratio
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 77 | 53 | 3 | - | 20 | 15 | 162 | 451 | 788 | - | - | - | - | - |
| Revenue growth (%) | - | - | - | - | - | - | - | - | ||||||
| Cost of revenue | - | - | - | - | - | - | 1 | 5 | - | - | - | - | - | - |
| Research & development | 31 | 37 | 39 | 46 | 81 | 94 | 122 | 161 | - | - | - | - | - | - |
| Selling, general & administrative | - | - | - | - | - | - | 170 | 249 | 354 | - | - | - | - | - |
| Operating margin (%) | - | - | - | - | - | - | ||||||||
| Operating income | 34 | 1 | -50 | -64 | -94 | -147 | -131 | 37 | 72 | - | - | - | - | - |
| Operating expenses | 43 | 52 | 53 | 64 | 114 | 162 | 293 | 414 | 716 | - | - | - | - | - |
| Income before tax | - | - | - | - | - | - | - | 22 | 47 | - | - | - | - | - |
| Pretax margin (%) | - | - | - | - | - | - | - | 4.8 | 5.9 | - | - | - | - | - |
| Provision for income taxes | - | - | - | - | - | - | - | 1 | 10 | - | - | - | - | - |
| Effective tax rate (%) | - | - | - | - | - | - | - | - | - | - | - | - | ||
| Net income | 38 | 5 | -46 | -61 | -89 | -141 | -143 | 21 | 37 | 407 | 90 | 155 | 250 | 341 |
| Net income margin (%) | - | - | - | - | - | - | ||||||||
| Earnings per share | 0.68 | 0.08 | -0.69 | -0.81 | -1.05 | -1.63 | -1.62 | 0.23 | 0.4 | - | - | - | - | - |
| Diluted EPS | 0.67 | 0.08 | -0.69 | -0.81 | -1.05 | -1.63 | -1.62 | 0.22 | 0.39 | - | - | - | - | - |